Regeneron Shares Now Reflect Valuation as Pipeline Visibility Becomes Key, Morgan Stanley Says

MT Newswires Live12-03

Regeneron (REGN) is trading generally in line with Morgan Stanley's valuation, and further visibility on pipeline diversification will be important for investors, the firm said in a Wednesday note.

Progress with Eylea HD approvals and strong Dupixent sales have supported the stock's rebound this year, with Dupixent annualizing near $20 billion, the note added.

Morgan Stanley also said it is watching Eylea dynamics, including label enhancements and patient foundation support, as well as rising research and development spending as the company advances programs such as its F11 antibody.

Morgan Stanley downgraded Regeneron to equal-weight from overweight and maintained its $767 price target.

Shares of the company were down over 1% in recent Wednesday trading.

Price: 733.21, Change: -8.79, Percent Change: -1.18

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588040155?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 23:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588040155","market":"us","top_or_hot":-1,"title":"Regeneron Shares Now Reflect Valuation as Pipeline Visibility Becomes Key, Morgan Stanley Says","media":"MT Newswires Live","content":"<html><body><p> Regeneron (REGN) is trading generally in line with Morgan Stanley's valuation, and further visibility on pipeline diversification will be important for investors, the firm said in a Wednesday note.</p><p>Progress with Eylea HD approvals and strong Dupixent sales have supported the stock's rebound this year, with Dupixent annualizing near $20 billion, the note added.</p><p>Morgan Stanley also said it is watching Eylea dynamics, including label enhancements and patient foundation support, as well as rising research and development spending as the company advances programs such as its F11 antibody.</p><p>Morgan Stanley downgraded Regeneron to equal-weight from overweight and maintained its $767 price target.</p><p>Shares of the company were down over 1% in recent Wednesday trading.</p><p>Price: 733.21, Change: -8.79, Percent Change: -1.18</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron Shares Now Reflect Valuation as Pipeline Visibility Becomes Key, Morgan Stanley Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron Shares Now Reflect Valuation as Pipeline Visibility Becomes Key, Morgan Stanley Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-03 23:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Regeneron (REGN) is trading generally in line with Morgan Stanley's valuation, and further visibility on pipeline diversification will be important for investors, the firm said in a Wednesday note.</p><p>Progress with Eylea HD approvals and strong Dupixent sales have supported the stock's rebound this year, with Dupixent annualizing near $20 billion, the note added.</p><p>Morgan Stanley also said it is watching Eylea dynamics, including label enhancements and patient foundation support, as well as rising research and development spending as the company advances programs such as its F11 antibody.</p><p>Morgan Stanley downgraded Regeneron to equal-weight from overweight and maintained its $767 price target.</p><p>Shares of the company were down over 1% in recent Wednesday trading.</p><p>Price: 733.21, Change: -8.79, Percent Change: -1.18</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1720051108.HKD","symbol_name":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2588040155","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588040155","pubTimestamp":1764776675,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Regeneron  is trading generally in line with Morgan Stanley's valuation, and further visibility on pipeline diversification will be important for investors, the firm said in a Wednesday note.Progress with Eylea HD approvals and strong Dupixent sales have supported the stock's rebound this year, with Dupixent annualizing near $20 billion, the note added.Morgan Stanley also said it is watching Eylea dynamics, including label enhancements and patient foundation support, as well as rising research and development spending as the company advances programs such as its F11 antibody.Morgan Stanley downgraded Regeneron to equal-weight from overweight and maintained its $767 price target.Shares of the company were down over 1% in recent Wednesday trading.Price: 733.21, Change: -8.79, Percent Change: -1.18","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0106831901.USD":"贝莱德世界金融基金A2","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","REGN":"再生元制药公司","LU0882574055.USD":"富达全球健康医疗A ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4585":"ETF&股票定投概念","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","BK4139":"生物科技","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","BK4127":"投资银行业与经纪业","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","BK4516":"特朗普概念","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","BK4504":"桥水持仓","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0557290698.USD":"施罗德环球可持续增长基金","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)"},"translate_title":"摩根士丹利表示，随着管道可见性成为关键，再生元股价现在反映了估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":1},"content_text":"Regeneron (REGN) is trading generally in line with Morgan Stanley's valuation, and further visibility on pipeline diversification will be important for investors, the firm said in a Wednesday note.Progress with Eylea HD approvals and strong Dupixent sales have supported the stock's rebound this year, with Dupixent annualizing near $20 billion, the note added.Morgan Stanley also said it is watching Eylea dynamics, including label enhancements and patient foundation support, as well as rising research and development spending as the company advances programs such as its F11 antibody.Morgan Stanley downgraded Regeneron to equal-weight from overweight and maintained its $767 price target.Shares of the company were down over 1% in recent Wednesday trading.Price: 733.21, Change: -8.79, Percent Change: -1.18","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588040155","isCrawlerRequest":true}